Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MPI | P34949 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3507130 | 1.00 | PTPN1 (0.36) | PTPN1LMNAL3MBTL1MPITDP1 | |
| SCHEMBL3507128 | 1.00 | PTPN1 (0.36) | PTPN1LMNAL3MBTL1MPITDP1 | |
| SCHEMBL5789757 | 1.00 | PTPN1 (0.36) | PTPN1LMNAL3MBTL1MPITDP1 | |
| SCHEMBL139867 | 0.89 | PTPN1 (0.38) | PTPN1MPI | |
| SCHEMBL6429913 | 0.89 | PTPN1 (0.38) | PTPN1MPI | |
| SCHEMBL29408337 | 0.83 | LMNA (0.42) | PTPN1LMNAL3MBTL1MPITDP1 | |
| SCHEMBL29431969 | 0.83 | LMNA (0.42) | PTPN1LMNAL3MBTL1MPITDP1 | |
| SCHEMBL7639200 | 0.81 | PTPN1 (0.38) | PTPN1MPI | |
| SCHEMBL3851271 | 0.79 | LMNA (0.39) | LMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL599665 | 0.79 | LMNA (0.39) | LMNAL3MBTL1TDP1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110142914-A1 | INHALABLE COMPOSITIONS HAVING ENHANCED BIOAVAILABILITY | CYTOTECH LABS, LLC (US) | 2011-06-16 | — | — | US | claimed |
| EP-2227085-A1 | INHALABLE COMPOSITIONS HAVING ENHANCED BIOAVAILABILITY | Cytotech Labs, LLC (US) | 2010-09-15 | — | — | EP | claimed |
| WO-2009073843-A1 | INHALABLE COMPOSITIONS HAVING ENHANCED BIOAVAILABILITY | CYTOTECH LABS, LLC (US) | 2009-06-11 | — | — | WO | claimed |
| CN-119979580-A | Method for producing 1, 3-dihydroxyacetone | 中国科学院天津工业生物技术研究所 | 2025-05-13 | — | — | CN | disclosed |
| CN-117957316-A | Fucosyltransferase for converting lactose-N-disaccharide | 因比奥斯公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117157396-A | Cell production of sialylated di-and/or oligosaccharides | 因比奥斯公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20210346291-A1 | INHALABLE PHARMACEUTICAL COMPOSITIONS | BPGBIO, INC. | 2021-11-11 | — | — | US | disclosed |
| CN-112980915-A | Method for evaluating toxic effect mechanism | 中国农业科学院农业质量标准与检测技术研究所 | 2021-06-18 | — | — | CN | disclosed |
| US-10973763-B2 | Inhalable pharmaceutical compositions | BERG LLC (US) | 2021-04-13 | — | — | US | disclosed |
| EP-2720680-B1 | INHALABLE PHARMACEUTICAL COMPOSITIONS | BERG LLC (US) | 2020-02-12 | — | — | EP | disclosed |
| US-10082499-B2 | Short term isotope pulse labeling method for analysing metabolic products in biological samples | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2018-09-25 | — | — | US | disclosed |
| US-20020161049-A1 | USE OF CREATINE OR CREATINE ANALOGS FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSYEM | LIBRARY PHARMA, INC. | 2002-10-31 | — | — | US | disclosed |
| WO-2002077209-A1 | TRANSGENIC PLANTS WITH RESISTANCE AGAINST TOBACCO RATTLE VIRUS AND CORRESPONDING NUCLEOTIDE SEQUENCE | PLANT SCIENCE SWEDEN AB (SE) | 2002-10-03 | — | — | WO | disclosed |
| WO-2002050281-A1 | VIRUS RESISTANCE IN PLANTS | PLANT SCIENCE SWEDEN AB (SE) | 2002-06-27 | — | — | WO | disclosed |
| EP-1065931-A1 | COMPOSITIONS CONTAINING A COMBINATION OF A CREATINE COMPOUND AND A SECOND AGENT | Avicena Group, Inc. (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-2001000212-A1 | USE OF CREATINE OR CREATINE ANALOGS FOR THE PREVENTION AND TREATMENT OF TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES | AVICENA GROUP, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| US-6169115-B1 | SUBSTRATES OR SUBSTRATE ANALOGS FOR CREATINE KINASE; | KADDURAH-DAOUK RIMA (US) | 2001-01-02 | — | — | US | disclosed |
| WO-1999051097-A1 | COMPOSITIONS CONTAINING A COMBINATION OF A CREATINE COMPOUND AND A SECOND AGENT | AVICENA GROUP, INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| EP-0804183-A1 | USE OF CREATINE OR CREATINE ANALOGS FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM | AVICENDA GROUP, INC. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996014063-A1 | USE OF CREATINE OR CREATINE ANALOGS FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM | AVICENA GROUP, INC. (US) | 1996-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161049-A1 | USE OF CREATINE OR CREATINE ANALOGS FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSYEM | CKMT1A; CKMT1B, PYGM, PC | PTPN1 1398/4885LMNA 2499/4885L3MBTL1 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.